Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novavax Looks To Secondary Endpoints As Phase III RSV Vaccine Trial Fails

Executive Summary

Novavax’s shares plunged 67% on news that its Phase III trial for RSV had failed, but are there signs of life for the product?

You may also be interested in...



Novavax Succeeds In Phase III Flu Vaccine Trial Against Sanofi’s Fluzone

Phase III trial could lead to mid-2020 BLA filing to prevent seasonal influenza in adults 65 and older. Novavax also talked up the potential value of its adjuvant in COVID-19 vaccine development.

Enanta Hopes To Succeed In RSV With N-Protein Inhibition Approach

Enanta's N-protein inhibitor EDP-938 hit a pair of endpoints in a Phase IIa challenge study, but real-world testing may be a higher hurdle. The company believes its therapeutic approach is more effective than fusion protein prophylactic approaches.

Alios Buy Best Forgotten For Johnson & Johnson As RSV Failure Costs It Dear

Johnson & Johnson has written off a further $700m against the RSV asset that it obtained with its $1.75bn purchase of Alios.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC124839

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel